Rgenta Therapeutics recipient of the Servier’s 2020 LabCentral Golden Ticket
We are committed to therapeutic progress to serve patient needs with the help of healthcare professionals. We strive to provide future generations with a world where quality healthcare is available and accessible to all.
Discover our 4 values:
Dare to innovate:
We undertake to provide innovative therapeutic solutions. Driven by a pioneering spirit, we dare, we strive, and we accomplish together.
We prepare for the future by embracing human and environmental dimensions. Our concern for the health and fulfillment of all is our driving force.
Grow by sharing:
Every opportunity to work together contributes to the common good. Whoever we are, wherever we are, we grow and develop by working together, building on one another’s experiences and contributions.
Commit to succeed:
The continuous development of the Group is vital. Whatever challenges we face, we are committed to keeping our promises.
patients treated each day
with Servier medicines.
of our turnover,
is reinvested in R&D.
€4.615 billion euros
in revenue comprising €3.2 billion
for brand-name medicines
€1.4 billion for generic medicines.
5 major R&D areas
cardiovascular, cancer, diabetes,
and neuropsychiatric diseases.
Servier signed a definitive agreement to acquire Symphogen, a leading antibody discovery company, to boost its antibody capabilities and leverage its R&D pipeline
Servier Laboratories Ltd
Sefton House, Sefton Park,
Bells Hill, Stoke Poges SL2 4JS
Tel: 01753 662744
Medical Enquiries: 01753 666409
Fax: 01753 663456